2m 2m 2m 2m 2m 2m 2m
- N/AMarket Cap
- -26.55%1-Year Change
- Diagnostics & ResearchIndustry
Bioqual (BIOQ)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
No data found
Peers
Statistics
MoreInformation as of 06/11/2026
Company Profile
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides contract research services in the areas of AIDS, influenza, respiratory syncytial virus, Coronavirus, malaria, hepatitis, cancer, and other infectious diseases, as well as flavivirus infections, including zika and dengue. It also offers small and large animal models. In addition, the company provides cell-based assays, immunoassay, toxicology and cytotoxicity testing, viral load testing, and tailored assay development services; and Biocontainment, imaging services, and animal model development; and IND-enabling services, such as toxicology studies, pharmacokinetic profiling, GLP services, and regulatory documentation services. Bioqual, Inc. was incorporated in 1981 and is based in Rockville, Maryland.
Key Executives
- Mitchell L. Franklin
- Hanne Andersen-Elyard
- Charles C. Kirk Jr.
Current Ownership Distribution
- Other681,298 (76.17%)
- Institutions210,000 (23.48%)
- Insiders3,118 (0.35%)
- Mutual Funds0 (0.00%)